The Filing Desk

NeoGenomics Laboratories vs Starling Oncology

NeoGenomics Laboratories NEO · Starling Oncology STLN · Health Care Services

NeoGenomics Laboratories reported revenue of $727 million in fiscal 2025, 1.4 times Starling Oncology's $503 million in fiscal 2025. NeoGenomics Laboratories' revenue grew 10.1% in its latest year, and Starling Oncology's grew 27.8%. NeoGenomics Laboratories had an operating margin of -15.9%, against -7.2% at Starling Oncology. Free cash flow was −$22 million at NeoGenomics Laboratories and −$28 million at Starling Oncology.

Side by side

NeoGenomics LaboratoriesStarling Oncology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$727M$503M
Revenue growth10.1%27.8%
Revenue growth a year, last 5 years10.4%21.8%
Gross margin43.2%—
Operating margin−15.9%−7.2%
Net margin−14.8%−12.1%
Free cash flow−$22M−$28M
Free cash flow margin−3.0%−5.5%
Return on capital−8.8%−75.7%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.1%23.1%
Last close$16.02$3.50
P/E at the last close——
Insider trades, last 12 monthssold $967,816—
Piotroski F-score5 of 93 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
NeoGenomics LaboratoriesStarling Oncology
Operating margin
Percent of revenue
NeoGenomics LaboratoriesStarling Oncology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NeoGenomics LaboratoriesStarling Oncology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the NeoGenomics Laboratories and Starling Oncology pages.